XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive tests to monitor immune status in transplant recipients and autoimmune diseases, today announced positive clinical results from the Company’s European-based Cardiac Allograft Rejection Gene Expression Observational II Study of AlloMap® Molecular ...
